Feature | October 10, 2013

Rare Fetal Cardiac Procedure Performed for First Time in Southern California

Specialists collaborate on aortic valvuloplasty on 25-week-old fetus

cardiovascular ultrasound structural heart valve repair hollywood presbyterian

A team of doctors at CHLA-USC Institute of Maternal-Fetal Health at CHA Hollywood Presbyterian Medical Center perform first fetal aortic valvuloplasty in utero in Southern California September 25

October 10, 2013 — A mother and her 25-week-old fetus are doing well after a team of physicians performed a successful in utero cardiac interventional procedure on the fetus at California Hospital Assn. (CHA) Hollywood Presbyterian Medical Center.

The minimally invasive procedure, known as a fetal aortic valvuloplasty, was a first for a Southern California hospital. Doctors succeeded in using a tiny balloon to open the fetus’s narrow aortic valve in order to increase blood flow to the body, improve left heart function and promote normal left heart growth during the critical third trimester growing stage.

Ramen Chmait, M.D., and Frank Ing, M.D., performed the procedure on Sept. 25 at Children’s Hospital Los Angeles. Collaborating for the first time, both physicians had performed the delicate fetal procedure before at hospitals outside of California.

“The surgery went beautifully; we were able to open up the aortic valve,” said Ing. “Fetal cardiac intervention is a relatively new field and requires expertise, commitment and collaboration among four specialty areas: pediatric interventional cardiology, fetal echocardiography, maternal-fetal-medicine and anesthesia.”

The patient, a 28-year-old Sylmar, Calif., mother of two, was 25 weeks pregnant at the time of procedure, which took a total of three hours and involved a team of 12, including physicians and support staff. Much of that time was devoted to Chmait’s maneuvering the fetus into position by manually adjusting the mother’s abdomen. With the assistance of a detailed ultrasound imaging by Children’s Hospital fetal cardiologist Jay Pruetz, M.D., Chmait inserted a special needle into the womb, through the fetal chest and into the peanut-sized heart’s left ventricle, positioning it below the aortic valve. As Chmait steadied the needle, Ing used Chmait’s hand as a platform for his hand to thread a hair-thin wire through the needle and out the tip, positioning the wire across the fetus’s aortic valve. The wire was then used as a rail for Ing to maneuver a tiny balloon-tipped catheter into position across the valve. Ing carefully inflated the balloon, which inflated to open the valve and increase blood flow into the aorta. The balloon, wire and needle were then removed.

The time from actual needle insertion to the balloon opening took roughly 15 minutes, Ing says. The mother was sedated during the procedure.

The fetal aortic valvuloplasty procedure has been completed more than 100 times in the United States., with most taking place at Boston Children’s Hospital. Only a handful of hospitals west of the Mississippi River have performed the procedure.

For more information: www.losangelesfetaltherapy.org, www.hollywoodpresbyterian.com

Related Content

Mitralign, Series E funding, Trialign, MPAS
News | Heart Valve Technology| May 23, 2016
Mitralign Inc. announced it has raised $39.8 million to date in a Series E equity round of financing.
TAVR outcomes, aortic valve gradient, JACC study
News | Heart Valve Technology| May 23, 2016
Patients with a combination of left ventricular dysfunction and low aortic valve gradient have higher mortality rates...
Direct Flow Medical, TAVR device, DISCOVER trial, three-year results, EuroPCR 2016
News | Heart Valve Technology| May 20, 2016
Direct Flow Medical Inc. presented three-year results from its prospective, multicenter DISCOVER Trial at the EuroPCR...
Watchman, left atrial appendage closure, LAA occluder, LAA. LAAO, laa occluder, left atrial appendage, Watchman

The Boston Scientific Watchman device is currently the only transcatheter LAA occluder cleared for use in the United States.

Feature | Left Atrial Appendage (LAA) Occluders| May 20, 2016 | Dave Fornell
Atrial fibrillation (AF) affects nearly 6 million Americans and the condition puts them at significantly greater risk
Bioventrix, Revivent-TC System, heart failure, first-in-man procedure
News | Heart Failure| May 19, 2016
BioVentrix announced the first-in-man use of its next-generation Revivent-TC System with an endovascular catheter-based...
St. Jude Medical, EuroPCR 2016 studies, FFR, LAAO, left atrial appendage occlusion, fractional flow reserve, Amplatzer
News | Cath Lab| May 19, 2016
St. Jude Medical Inc. announced results from two cardiovascular clinical trials presented at EuroPCR 2016.
RDAVR, aortic valve replacement, Edwards Intuity, TRANSFORM Trial, AATS meeting
News | Heart Valve Technology| May 18, 2016
The TRANSFORM trial was designed to evaluate the safety and performance of an investigational rapid deployment aortic...
Technology | Cardiac Imaging| May 18, 2016
May 18, 2016 — The Intersocietal Accreditation Commission (IAC) recently announced its launch of the IAC QI Self-Asse
NeoChord, DS1000 System, FDA approval, U.S. pivotal trial
News | Heart Valve Technology| May 17, 2016
NeoChord Inc. announced it has received Investigational Device Exemption (IDE) approval from the U.S. Food and Drug...
4Tech Inc., TriCinch transcatheter tricuspid valve repair device, Jean-Claude Laborde

Image courtesy of 4Tech Inc.

News | Heart Valve Technology| May 16, 2016
4Tech Inc. announced its partnership with Jean-Claude Laborde, M.D., as a research and development (R&D) and...
Overlay Init